- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Matrix protein.
Displaying page 1 of 2.
EudraCT Number: 2019-002872-14 | Sponsor Protocol Number: VAC079 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK | |||||||||||||
Medical condition: Plasmodium vivax malaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001831-23 | Sponsor Protocol Number: 3100N7-210 WW | Start Date*: 2007-01-23 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures | |||||||||||||
Medical condition: Closed diaphyseal tibial fracture | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Completed) DE (Prematurely Ended) FI (Completed) GB (Completed) LV (Completed) SI (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012672-27 | Sponsor Protocol Number: CIP0702PLF/EU | Start Date*: 2009-08-17 | |||||||||||
Sponsor Name:ApaTech Limited | |||||||||||||
Full Title: "A prospective, randomised study comparing the use of Actifuse™ ABX synthetic bone substitute with INFUSE® in patients requiring posterolateral instrumented lumbar fusion with interbody fusion" als... | |||||||||||||
Medical condition: Prospective trial participants will have been diagnosed with degenerative disc disease with a treatment option of decompression and Interbody Fusion with Posterolateral Intertransverse Process Fusi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000328-85 | Sponsor Protocol Number: FINNHT1 | Start Date*: 2017-05-18 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001793-36 | Sponsor Protocol Number: GTX-102-001 | Start Date*: 2023-04-26 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) | ||
Medical condition: Angelman Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005787-22 | Sponsor Protocol Number: EP395-003 | Start Date*: 2022-07-21 | |||||||||||
Sponsor Name:EpiEndo Pharmaceuticals | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD) | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000146-36 | Sponsor Protocol Number: EMD72000-032 | Start Date*: 2005-07-28 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects w... | |||||||||||||
Medical condition: Metastatic Esophago-gastric adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001724-35 | Sponsor Protocol Number: AMASCIS-02 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP) | |||||||||||||
Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL. | |||||||||||||
Medical condition: Moderate-severe ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003408-65 | Sponsor Protocol Number: | Start Date*: 2016-08-26 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial) | ||||||||||||||||||
Medical condition: Heavy menstrual bleeding | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002387-16 | Sponsor Protocol Number: SI-C-060 | Start Date*: 2015-11-16 | |||||||||||
Sponsor Name:Solvotrin Innovations Ltd | |||||||||||||
Full Title: The Role of Tetracyclines in the Personalised Management of MMP-9 and Cardiovascular Function in Type 2 Diabetes | |||||||||||||
Medical condition: Type II diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003131-35 | Sponsor Protocol Number: AA-HPP-208 | Start Date*: 2016-04-19 | |||||||||||
Sponsor Name:Alexion Pharma GmbH | |||||||||||||
Full Title: A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia | |||||||||||||
Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-no... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004152-19 | Sponsor Protocol Number: ELASTIC2011 | Start Date*: 2012-04-18 | |||||||||||
Sponsor Name:Ludwig Boltzmann institute for COPD and Respiratory Epidemiology | |||||||||||||
Full Title: Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial | |||||||||||||
Medical condition: chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003859-12 | Sponsor Protocol Number: 12-027 | Start Date*: 2013-07-19 | ||||||||||||||||
Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A) | ||||||||||||||||||
Full Title: Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus | ||||||||||||||||||
Medical condition: patients with type 2 diabetes mellitus and vascular inflammation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001929-40 | Sponsor Protocol Number: AZT_DSTB_BB | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis | |||||||||||||
Medical condition: Pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000942-14 | Sponsor Protocol Number: 0243CT01 | Start Date*: 2022-10-20 |
Sponsor Name:Kissei Pharmaceutical Co., Ltd. | ||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, multicentre study of a once daily multiple oral administration of KSP-0243 in patients with mild-to-moderate ulcerative colitis | ||
Medical condition: Ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: RO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002833-13 | Sponsor Protocol Number: AMT-101-203 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Sev... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000048-73 | Sponsor Protocol Number: AMT-101-201 | Start Date*: 2020-09-24 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis | |||||||||||||
Medical condition: Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004034-11 | Sponsor Protocol Number: GR-OG-279239-04 | Start Date*: 2022-05-18 | ||||||||||||||||
Sponsor Name:Genera Research Ltd | ||||||||||||||||||
Full Title: A randomized, evaluator-blinded, dose-ranging, proof of concept study of efficacy, safety and tolerability of Osteogrow-C (rhBMP6 delivered in autologous blood coagulum [ABC] supplemented with sy... | ||||||||||||||||||
Medical condition: The treatment of non-union of the tibia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001626-26 | Sponsor Protocol Number: OMT28-C0201 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:OMEICOS Therapeutics GmbH | |||||||||||||
Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (... | |||||||||||||
Medical condition: Persistent atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
